Tarsus Pharmaceuticals【TARS】銘柄情報

Tarsus Pharmaceuticals Inc (TARS) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

62.70

( 0.14% )

買値

25.05

売値

65.00

出来高

517

0.00 日の範囲 0.00

38.51 52 週間の範囲 85.25

時価総額

2.698B

前日終値

62.61

始値

時刻

62.76

最終取引時間

17:36:29

財務取引量

VWAP

平均取引量 (3 か月)

US$ 618,339

発行済株式数

43,023,959

配当利回り

PER

-54.44

1 株当たり利益 (EPS)

-1.13

歳入

535.08M

純利益

-48.27M

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the ... Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

tarsusrx.com

本社

Irvine, United States

設立

2026

Tarsus Pharmaceuticals Inc is listed in the Healthcare sector of the ナスダック市場 with ticker TARS. The last closing price for Tarsus Pharmaceuticals was US$62.61. Over the last year, Tarsus Pharmaceuticals shares have traded in a share price range of US$ 38.51 to US$ 85.25.

Tarsus Pharmaceuticals currently has 43,023,959 shares in issue. The market capitalisation of Tarsus Pharmaceuticals is US$2.70 billion. Tarsus Pharmaceuticals has a price to earnings ratio (PE ratio) of -54.44.

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc...

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	1.84	3.02333223792	60.86	64.59	58.49	429658	60.91994804	CS
4	-2.3	-3.53846153846	65	65.98	56	674024	60.59474645	CS
12	-4.05	-6.06741573034	66.75	74.39	56	625196	63.41322594	CS
26	-19.63	-23.8430705697	82.33	84.07	56	628334	68.6138343	CS
52	21.82	53.3757338552	40.88	85.25	38.51	615600	62.52760602	CS
156	44.66	247.56097561	18.04	85.25	12.57	632645	42.8820561	CS
260	27.58	78.5307517084	35.12	85.25	10.8001	417402	40.45047764	CS